Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18174162 | 0.88 | GPR84 (0.42) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10361722 | 0.72 | GPR84 (0.44) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18174042 | 0.72 | GPR84 (0.42) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL877751 | 0.72 | HSD17B10 (0.50) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18174069 | 0.72 | BCAT2 (0.37) | NPC1RAB9ASMN1; SMN2MAPTPKM | |
| SCHEMBL29714643 | 0.71 | NPC1 (0.53) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17709309 | 0.71 | NPC1 (0.53) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7292520 | 0.71 | MAPT (0.46) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5658471 | 0.70 | CES1 (0.44) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29050604 | 0.70 | NPC1 (0.51) | GPR84KDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| EP-3286191-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016169911-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | GPR84 1/4885KDM4E 3499/4885NPC1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.